Gencia teams with Takeda in $500M deal to develop mitochondrial therapeutic alternative to steroids
Virginia startup Gencia is developing a mitochondrial therapeutic that could prove an alternative to the widely prescribed steroid. It just entered a deal worth up to $500 million with Japanese pharma giant Takeda.